Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
about
sameAs
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaClinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case-control studyInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.Approach to chemotherapy-associated thrombosis.Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical MethodologiesErythropoietin treatment in murine multiple myeloma: immune gain and bone loss.Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence.Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies.Thromboembolic risk in hematological malignancies.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.A review of the venous thrombotic issues associated with multiple myeloma.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.Rare and unusual case of anti-factor XI antibodies in patient with plasma cell leukemiaVenous thromboembolism during treatment with antipsychotics: Results of a drug surveillance programmeLonger procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re
P2860
Q33413142-A2569EAD-EB33-4F94-A7CA-1143965F4A1FQ33433453-769CB6C1-644F-41C8-AB06-5117BF3C203AQ34539519-A280448A-3E39-41E6-A7B2-FBE7D3711429Q35579010-AB17F52B-69AF-4352-BF85-62E7EDF3368AQ35802414-DE06D73D-A726-4BD3-A831-4ACEA198192AQ36229918-0DEB7E03-272A-4339-A28B-1ECD6B76886BQ36304793-A6510558-55C1-4FFA-8A35-B45CAB1D96F1Q37069353-DF85C92A-08F3-4DE5-AB9D-BD938D0113BEQ37144501-F5585E25-6B81-4A68-8FE8-D6E11E6E3031Q38035031-E6E2776C-BDE2-4F21-B611-462D90C9EA1EQ38176847-DD0F1EF4-A613-4B7F-A667-CBBE933E7730Q38287304-1E350748-0345-4C38-B98B-DA40DCFF556BQ38555091-7AA540CE-3B01-4098-AAEB-91338CCA7499Q38845946-F7549D5B-EB1E-475E-98F0-1B20D1723FEBQ39100317-F799B806-9405-4014-A02B-84FA83CE4116Q49048515-E123C3F6-461B-4F00-AAFE-226D9CDC5ADBQ50916755-C246AA9D-AD16-4BC3-BF27-2A484874E5D8Q56523652-DFD1ABED-8189-45EB-BD90-F55BC07797DAQ57737811-15159F5F-786E-44ED-B73D-F1F3ED0A4DA5Q58592860-DB1EB2FC-6545-44A4-BFC7-3BF5B2384CF5
P2860
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
description
im April 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 31 March 2011
@en
wetenschappelijk artikel
@nl
name
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
@en
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
@nl
type
label
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
@en
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
@nl
altLabel
Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis
@en
Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of Thrombosis
@nl
prefLabel
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
@en
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
@nl
P2093
P356
P1476
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis
@en
P2093
Beatrice Zannetti
Elena Zamagni
Lucia Pantani
Paola Tacchetti
P304
P356
10.1055/S-0031-1273085
P407
P577
2011-03-31T00:00:00Z